Eukles Asset Management Cuts Stock Position in Masimo Co. (NASDAQ:MASI)

Eukles Asset Management lowered its position in Masimo Co. (NASDAQ:MASI) by 4.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 8,864 shares of the medical equipment provider’s stock after selling 456 shares during the period. Eukles Asset Management’s holdings in Masimo were worth $1,039,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Masimo by 9.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 7,914 shares of the medical equipment provider’s stock valued at $928,000 after acquiring an additional 713 shares during the period. Harel Insurance Investments & Financial Services Ltd. acquired a new stake in Masimo during the 4th quarter valued at approximately $36,000. Sumitomo Mitsui Trust Holdings Inc. lifted its stake in shares of Masimo by 2.1% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 413,815 shares of the medical equipment provider’s stock valued at $48,503,000 after purchasing an additional 8,498 shares during the period. Louisiana State Employees Retirement System acquired a new position in shares of Masimo in the 4th quarter valued at $1,465,000. Finally, Byrne Asset Management LLC acquired a new position in shares of Masimo in the 4th quarter valued at $28,000. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. Stifel Nicolaus upgraded shares of Masimo from a “hold” rating to a “buy” rating and boosted their target price for the company from $148.00 to $170.00 in a research note on Monday. Jefferies Financial Group restated a “hold” rating and set a $121.00 price objective (up from $107.00) on shares of Masimo in a research report on Tuesday, January 30th. Wells Fargo & Company upgraded shares of Masimo from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $117.00 to $160.00 in a research report on Monday, March 25th. BTIG Research raised their price objective on shares of Masimo from $145.00 to $166.00 and gave the company a “buy” rating in a research note on Monday, March 25th. Finally, StockNews.com raised shares of Masimo from a “sell” rating to a “hold” rating in a research note on Friday, March 29th. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $137.43.

Masimo Stock Down 0.9 %

Masimo stock traded down $1.22 during trading on Friday, reaching $134.70. The stock had a trading volume of 114,697 shares, compared to its average volume of 573,745. The stock has a market cap of $7.13 billion, a PE ratio of 90.01 and a beta of 0.97. The business has a 50 day moving average price of $135.66 and a 200 day moving average price of $114.20. The company has a quick ratio of 1.22, a current ratio of 2.18 and a debt-to-equity ratio of 0.64. Masimo Co. has a 52-week low of $75.22 and a 52-week high of $198.00.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 27th. The medical equipment provider reported $1.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.43. Masimo had a return on equity of 13.77% and a net margin of 3.98%. The business had revenue of $548.90 million during the quarter, compared to analysts’ expectations of $545.69 million. During the same period in the prior year, the firm posted $1.32 EPS. The business’s quarterly revenue was down 11.0% compared to the same quarter last year. On average, analysts predict that Masimo Co. will post 3.51 EPS for the current year.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.